Skip to main content

Table 2 Summary of the pooled safety outcome

From: Integrase inhibitors versus efavirenz combination antiretroviral therapies for TB/HIV coinfection: a meta-analysis of randomized controlled trials

Outcome or subgroup Studies Cases No. with event/total no. of patients
INIs and EFV
Effect estimate (RR and 95% CI)
Any AEs 2 215 98/120 and 86/95 0.92 (0.76,1.11)
 DTG vs. EFV 1 113 52/69 and 40/44 0.83 (0.70,0.98)
 RAL vs. EFV 1 102 46/51 and 46/51 1.00 (0.88,1.14)
Drug-related AEs 3 674 50/349 and 54/325 0.80 (0.57,1.14)
 DTG vs. EFV 1 113 19/69 and 14/44 0.87 (0.49,1.54)
 RAL vs. EFV 2 561 31/280 and 40/281 0.78 (0.50,1.21)
Discontinuation for drugs 3 674 2/349 and 8/325 0.30 (0.08,1.09)
 DTG vs. EFV 1 113 0/69 and 2/44 0.13 (0.01,2.62)
 RAL vs. EFV 2 561 2/280 and 6/281 0.39 (0.09,1.64)
Grade 3–4 AEs 3 674 78/349 and 87/325 0.89 (0.68,1.15)
 DTG vs. EFV 1 113 3/69 and 2/44 0.96 (0.17,5.50)
 RAL vs. EFV 2 561 75/280 and 85/281 0.89 (0.68,1.15)
IRIS (Grade 3–4) 3 674 13/349 and 20/325 0.63 (0.32,1.25)
 DTG vs. EFV 1 113 1/69 and 1/44 0.64 (0.04,9.93)
 RAL vs. EFV 2 561 12/280 and 19/281 0.63 (0.31,1.28)
Death 3 672 13/350 and 16/322 0.80 (0.39,1.64)
 DTG vs. EFV 1 113 0/69 and 0/44 NA
 RAL vs. EFV 2 559 13/281 and 16/278 0.80 (0.39,1.64)